SCHEDULE 4

PART I CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

F15

A liquid formulation—

a

containing a botanical extract of cannabis—

i

with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and

ii

where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,

b

which is dispensed through a metered dose pump as a mucosal mouth spray, and

c

which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010